Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

First Amendment Suit: FDA Draws The Line At Amarin's Heart Disease Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Trying to forestall preliminary injunction, FDA's Woodcock doesn't object to Amarin's reprint distribution, but says firm needs strong incentive to complete its cardiovascular outcomes study.



Related Companies